Table 2.
Gene | Dosage | Number and percent of fingerlings with anomaly* | Total number | |||
---|---|---|---|---|---|---|
Absence of eye development | Absence of barbel | Deformed head | Spinal deformity | |||
TICAM1 | Low | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 50 |
Medium | 0 (0%) | 0 (0%) | 2 (15.4%) | 0 (0%) | 13 | |
High | 0 (0%) | 1 (6.3%) | 3 (18.8%) (two were mutated, one was not) | 0 (0%) | 16 | |
RBL | Low | 2 (7.7%) | 0 (0%) | 1 (3.8%) | 1 (3.8%) | 26 |
Medium | 1 (10%) | 0 (0%) | 0 (0%) | 0 (0%) | 10 | |
High | 1 (7.7%) | 0 (0%) | 0 (0%) | 0 (0%) | 13 |
Three dosages for each gene were injected including low dosage: 2.5 ng gRNA/7.5 ng Cas9 protein, medium dosage: 5 ng gRNA/15 ng Cas9 protein and high dosage: 7.5 ng gRNA/22.5 ng Cas9 protein. All injected and non-injected 4-month-old control fry were free of any anomalies (see Fig. 3).
*All fingerlings with anomalies were mutated except one from the TICAM 1 high dosage that had head deformity but was not mutated.